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Abstract— Acoustic cluster therapy (ACT) is designed to 
overcome some of the limitations of conventional microbubbles 
for ultrasound-assisted delivery of drugs to tumors. ACT consists 
of clusters of oil microdroplets and microbubbles. Diagnostic 
ultrasound imaging can be used to visualize the microbubble 
component and to activate (vaporize) the droplets to produce 
large (>20 µm) bubbles which lodge in the tumor’s microvessels. 
A subsequent low-frequency ultrasound field then gently pulsates 
the activated bubbles which are in direct contact with 
endothelium, enhancing vascular permeability. We present in-
vivo pre-clinical imaging experiments designed to better 
understand ACT behavior. Conventional microbubbles were 
observed to wash out of tumors within 6 min whereas activated 
ACT failed to wash out during the observation time of 15 min, 
confirming activation. Stationary echoes in tumors uniquely 
accumulated in fundamental B-mode images after ACT 
activation (but not with a microbubble agent, nor in nonlinear 
contrast mode) providing a signature for identifying ACT 
activation in vivo. ACT significantly enhanced CW800 dye 
uptake in tumor relative to dye alone. Photoacoustic CW800 
signals appeared in the tumor periphery, suggesting potential for 
high-resolution, three-dimensional dynamic monitoring although 
with lower sensitivity than fluorescence imaging.   
Keywords — ACT, cancer treatment response, drug delivery, 
imaging biomarker, microbubble 
I. INTRODUCTION 
The combination of ultrasound and intravenously injected 
microbubbles can improve drug delivery to tumors, also 
reducing systemic dose and toxicity [1]. Nevertheless, 
microbubbles have several limitations, which include limited 
capacity to carry drugs on their surface, small and brief local 
dose enhancement as the drug flows downstream and limited 
ability to interact with the vascular endothelium to increase 
permeation due to small surface area and relatively large 
distance from the endothelium. Acoustic cluster therapy (ACT) 
is designed to overcome some of these limitations. It consists 
of a dispersion of clusters of positively charged oil 
microdroplets that are electrostatically bound to negatively 
charged microbubbles (Fig. 1). The droplets could carry a 
dissolved drug or the whole product may be co-injected with a 
drug. Full details of ACT are provided in [2]. Diagnostic 
ultrasound is able to visualize the microbubbles and to activate 
(vaporize) the droplets to produce large (> 20 µm) bubbles 
which lodge in the tumor’s microvessels and may briefly trap 
released or co-injected drug. A low-frequency ultrasound field 
is then employed to gently pulsate the activated bubbles which 
are in contact with a relatively large section of the vascular 
endothelium, increasing vascular permeability.  
For fully effective future deployment of the ACT concept, 
imaging methods would ideally needed to monitor 
accumulation of non-activated agent for dosimetry, confirm 
and quantify activation and its spatial distribution, and monitor 
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Figure 1. Illustration of the acoustic cluster therapy (ACT) 
concept. Although a drug-loaded microdroplet is shown, 
unloaded agent may be co-injected with a drug. 
 
Figure 2. Apparatus for in-vivo ACT imaging, activation 
and delivery-enhancement. 
the delivery enhancement and its duration. Here we present in-
vivo pre-clinical ultrasound, optical and photoacoustic imaging 
experiments designed to better understand ACT behavior. We 
extend previous work [3] by using different tumor models, 
apparatus for imaging and delivery enhancement, and signal 
processing. 
II. MATERIALS AND METHODS 
A. Confirming acoustic cluster activation  
An ovarian carcinoma (SK-OV-3, subline SLC-B) 
xenograft was grown as a subcutaneous tumor on the lower 
right flank of each of 6 athymic mice. Imaging and activation 
of ACT used a Toshiba Aplio-XG ultrasound scanner and a 
1204BT linear array. Radiofrequency data and video image 
sequences were acquired for both fundamental and non-linear 
contrast modes, at 8 MHz, before, during and after intravenous 
ACT injection.  
Initial studies confirmed that it was possible to detect the 
acoustic clusters arriving at the tumor without activating the 
agent, by setting the mechanical index (MI = PNP/(fc)
½
, where 
PNP = peak negative pressure and fc = center frequency [4]) to 
a low enough value, typically less than 0.1. At such low MIs, 
acoustic clusters were visible as moving echoes in nonlinear 
contrast-specific imaging mode but were not visible in 
conventional fundamental B-mode images, which suggested 
that it was the microbubble component of the clusters that was 
producing the detectable nonlinear echo signal. 
By increasing the MI, imaging evidence suggested that the 
agent was being activated. Above an MI of 0.1, stationary 
echoes were observed to appear in the fundamental B-mode 
images of a tumor which previously had shown little or no 
contrast enhancement on B-mode, consistent with the 
production of large trapped bubbles.  To test that these 
stationary echoes were uniquely associated with the activation 
of ACT clusters, echo time-amplitude curve (TAC) properties 
were measured for mobile and stationary contrast agent 
components, in tumor regions of interest following Sonazoid™ 
(microbubble only) injections, compared with injections of 
ACT clusters. To be able to simultaneously generate separate 
time-amplitude curves for mobile versus stationary bubbles an 
image processing method was developed to segment stationary 
from moving echoes. This involved first characterizing the 
respiratory motion by using speckle tracking, then using this to 
apply a correction for such motion, after which images of echo 
temporal correlation were calculated and thresholded. After 
such processing, moving-bubble echoes exhibited low 
correlation. Stationary bubbles possessed high correlation and 
appeared in fundamental B-mode as new echoes since prior to 
injection. 
B. Reporter dye delivery-enhancement studies 
Unlike in our previous study [3], which employed partial 
immersion of the animal in a water-tank, reporter dye delivery-
enhancement studies were conducted here using a clinically-
translatable experimental apparatus (Fig. 2). Tail-vein injection 
of 100 µl, 2 nmol 800CW™ PEG infrared (IR) dye, with or 
without subsequent injection of ACT, was followed by 
delivery-enhancement insonification using 300 kHz ultrasound 
from a single element bowl transducer focused on the tumor.  
ACT was administered in 3, 50 µl does, with 5-minute 
intervals between doses, and activated at the tumor site for 45 s 
immediately after injection using the Toshiba Aplio™ at 
8 MHz operating in interleaved (10 frames/sec) non-linear 
contrast mode and fundamental B-mode, and at an MI of 0.4. 
Each administration of ACT and activation insonification was 
followed by insonification for delivery enhancement for 5 min 
using 300 KHz, 2-cycle pulses of ultrasound at a pulse 
repetition frequency of 2 kHz and MI of 0.12. 
An IVIS™ SpectrumCT imaging system was then used to 
measure dye epifluorescence in the SK-OV-3 tumors compared 
to background.  
As a preliminary study of photoacoustic monitoring of 
CW800 reporter-dye accumulation following ACT treatment, a 
subcutaneous pancreatic adenocarcinoma (MiaPaCa-2) tumor 
on the flank of a mouse was employed, scanned using a 
preclinical whole-body cross-sectional multispectral 
optoacoustic tomography (MSOT) system (iThera inVision256 
MSOT™). MSOT images at various optical wavelengths in the 
range 680 – 900 nm were obtained and co-registered with 
ultrasound fundamental B-mode and non-linear contrast 
 
Figure 3. Ultrasound images of an SK-OV-3 tumor pre- 
and 60 s post-ACT injection (MI = 0.4). 
 
Figure 4. Example frames from image sequences at 
MI = 0.4, overlaid with contrast echoes segmented as 
stationary (red). Left: pre-injection. Middle: 10 s after 
injection. Right: 120 s after injection. Top: ACT was 
injected. Bottom: Sonazoid™ was injected. 
 
Figure 5. Maximum stationary echo number density as a 
function of incident MI value for Sonazoid™  and ACT. 
images obtained at 8 MHz using the above-mentioned Aplio™ 
scanner. A novel system, reported elsewhere [5], was used to 
register the ultrasound images to the MSOT images. 
Single-wavelength and spectrally-unmixed MSOT images 
were compared with IVIS™ fluorescence images.  
III. RESULTS AND DISCUSSION 
A. Acoustic cluster activation effectiveness 
Stationary echoes in tumors uniquely accumulated in 
fundamental mode after ACT injection and ultrasound 
activation, but they were not seen when Sonazoid™ alone was 
injection, nor in nonlinear contrast mode whether ACT or 
Sonozoid™ was injected, nor when ACT was injected and an 
insufficient (non-activating) MI was employed. This behavior 
was apparent by subjective observation of image sequences 
(Fig. 3) and after image processing to automatically identify 
activated clusters, providing a signature with which to identify 
and count the level of ACT activation in vivo (Fig. 4).  The 
peak number of stationary activated ACT bubbles tended to 
increase as a function of MI, from MI = 0.1 to 0.4 (Fig. 5). 
Clear differences were observed between the temporal 
dynamics of Sonazoid™, ACT, and moving and stationary 
components of ACT, as a function of MI. From the TAC 
properties (Fig. 6), the peak for Sonazoid™ mobile contrast 
accumulation in tumors was 5 – 10 s post-injection, compared 
with 30 – 120 s for activated ACT clusters. Sonazoid™ 
microbubbles washed out of the tumor within 6 min whereas 
activated ACT failed to wash out within the observation time 
(15 min), confirming activation.  
B. Reporter dye delivery-enhancement 
ACT significantly enhanced CW800 uptake in SK-OV-3 
tumors, by a factor of 1.4 fluorescence intensity relative to dye 
alone (Fig. 7), as measured by fluorescence in the tumor 
relative to background. This is of particular significance since 
this dye is designed for use as an agent for enhanced 
permeation and retention (EPR). The uptake enhancement level 
achieved using ACT was comparable to that observed 
previously in mice [3] with the same infrared dye but using a 
different (human prostate) tumor model and insonation 
arrangement, which lends confidence to the reproducibility of 
results using ACT for enhancing delivery of surrogate 
therapeutics to tumors. 
In the MiaPaCa-2 tumor, six days post-dye injection and 
ACT treatment, dye accumulation observed in the 
epifluorescence image was consistent with the behavior 
expected for an EPR agent with fluorescence remaining high in 
the tumor (Fig. 8a). Prior to that, tumor-to-background ratio 
increased from 2.37 to 6.77 between 150 min and 6 day post-
injection and ACT treatment. MSOT spectrally-unmixed 
images using all wavelengths demonstrated ability to isolate 
hemoglobin, oxyhemoglobin and CW800 chromophores (Fig. 
8d). Using these and images obtained at the dye’s absorption 
peak of 770 nm (Fig. 8c), photoacoustic CW800 signals were 
observed in the tumor periphery (Figs. 8c and 8d), suggesting 
potential for using MSOT to measure the spatio-temporal 
dynamics of reporter dye uptake at high resolution in three 
dimensions if more dye were to be injected. 
IV. CONCLUSIONS 
Stationary new echoes in fundamental B-mode ultrasound 
images identify activated ACT clusters in vivo, and ACT 
significantly enhances uptake of an infrared dye acting as a 
surrogate therapeutic. These findings demonstrate 
reproducibility of previous observations in a different tumor 
model and using different insonification apparatus. The 
 
Figure 6. Example TAC curves showing rate of tumor wash-in and wash-out, MI=0.4   a) all echoes, b) segmented new 
stationary echoes, c) segmented moving echoes. 
 
Figure 7. CW800 infrared dye uptake enhancement using 
ACT. The tumor/background epifluorescence for CW800 
dye alone is compared with that for CW800 dye followed 
by ACT activation and delivery enhancement sonification 
with pulsed 300 kHz and MI = 0.12 (means, ±1 standard 
deviation, N = 3). 
 
Figure 8. Images of a subcutaneous pancreatic 
adenocarcinoma xenograft (MiaPaCa-2) 6 days after 
injection of 2 nmol CW800 dye followed by ACT 
activation and delivery enhancement sonification. (a) 
Epifluorescence image of the whole mouse showing the 
tumor as strongly fluorescing. (b) Ultrasound B-mode 
image at 8 MHz of the tumor in cross-section. (c) co-
registered MSOT tumor cross-sectional image at 770 nm. 
(d) Image from (b) overlaid with a spectrally unmixed 
MSOT image showing oxyhemoglobin (red), hemoglobin 
(blue) and CW800 (green). 
imaging/insonification apparatus employed here has potential 
for translation to the clinic, especially if both imaging and 
delivery-enhancement ultrasound beams can be generated by 
the same transducer. 
MSOT photoacoustic imaging shows potential for high-
resolution three-dimensional dynamic monitoring, albeit with 
lower sensitivity than epifluorescence imaging. 
The methods developed to automatically segment 
stationary bubble (activated acoustic clusters) echoes from 
moving bubble (microbubble) echoes may also be of value in 
fields such as the study of molecularly targeted bubbles, to 
determine which bubbles have bound to their target. For future 
applications of ACT, in delivering actual therapeutics as well 
as dye surrogates, the method developed for counting 
integrated amplitude of stationary new echoes as a measure of 
activation efficiency would be worth evaluation as a predictor 
of enhancement of uptake and hence response to treatment.  
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